Effects On Anti-tumor And Immunoregulatory Activity Of Argopectens Irradias Glycoprotein In Mice

To investigate the anti-tumor activity and the influence on immunologic function in mice of glycoprotein from Argopectens irradias(AIG), the research selected Kunming mice as experimental animals. S180 tomor-bearing mice were used as animal model. The experiment setted three AIG dose groups (80, 160, 320 mg/kg·bw), a solvent control group and a model control group (for anti-tumor research). The tumor growth were measured, the effects on spleen cell apoptosis and T-Lymphocyte Subsets were determined by flow cytometry. Also, we observed the influence of AIG on mice immune function. The results were as follows:1. Effects of AIG on tumor weights in S180 tumor-bearing miceThe results indicated that tumor weights were decreased significantly in a dose dependent manner in AIG treated groups compared with the control group (P<0.01).The inhibitory rates were 31.83%、34.50% and 36.36% in the low-dose, middle-dose and high-dose AIG groups respectively.2. Effects of AIG on apoptosis of spleen lymphocytes in S180 tumor-bearing miceThe results indicated, compared with the control group, all doses of AIG can inhibit the apoptosis of splenic lymphocytes of S180 tumor-burdened mice. Early apoptosis rate and total apoptosis rate had a positive correlation with the dose of AIG, which means the high- dose (320mg/kg·bw) is the most effective one (P<0.05).3. Effects of AIG on the percentage of T cell subsets in S180 tumor-bearing mice peripheral bloodThe results indicated that the proportion of the CD8~+ T cell was not affected, the percentage of CD3~+ T cells and CD4~+ T cells were significantly increased in middle-dose and high-dose groups that compared with control group(P<0.05, P<0.01). Furthermore, there was a definite trend toward an increased ratio of CD3~+ T cell, CD4~+ T cell and CD4~+/CD8~+ in the AIG administered groups in dose-dependent manner. This increase of the ratio may be achieved the best effect when the mice were administered with high-dose of AIG.4. Effects of AIG on the relative quality of immune organs in miceThe results indicated, the relative quality of the immune organs in the administrated mice were higher than that in the control group, and dose-dependent manner existsed. High-dose group in which the relative quality of the spleen increased by 41.10% (P<0.01) compared with the control group, the relative quality of thymus increased by 53.10% (P<0.05) that compared with the control group.5. Effects of AIG on cellular immune function in miceSelected spleen lymphocyte transformation test and delayed hypersensitivity test to observe cellular immune function of mice administrated. The results indicated that the degree of foot swelling and spleen lymphocyte transformation rates in the administrated groups were higher than that in the control group, and the dose-dependent manner existed, in which the spleen lymphocyte transformation rate in middle-dose and high-dose groups increased by 31.81%(P<0.05) and 72.73%(P<0.01) than that compared with the control group. The degree of swelling of the foot in middle-dose and high-dose groups increased by 48.15% (P<0.01) and 55.56% (P<0.01) than that compared with the control group.6. Effects of AIG on humoral immunity function in miceSelected spleen plaque hemolytic test to observe the influence of AIG on mice humoral immune function. The results indicated that the PFC values in the administrated groups were higher than that in the control group, the dose-dependent manner existed. Among them, the numerical of PFC value in middle-dose group increased by 0.90% (P<0.05) than that compared with the control group, morever, this rate increased by 4.13% (P<0.01) in high-dose group.Conclusion: Within the dose between 80~320mg/kg·bw, AIG can enhance the cellular immune function and humoral immunity function in mice. Also, AIG had some anti-tumor effect, this kind of activity may result from restraining the apoptosis of spleen cells in S180 tumor-bearing mice and upregulating the percentage of CD3~+ T cell, CD4~+ T cell and CD4~+/CD8~+ in S180 tumor-bearing mice peripheral blood.